Tempest Therapeutics Licensing Deal with Hebei Senlang Biotechnology Co., Ltd.
Tempest Therapeutics has exercised its option to obtain an exclusive license for Senlang’s CD7-targeted lentiviral in vivo CAR-T platform and associated candidates worldwide, excluding China. The deal includes the lead BCMA/GPRC5D dual-targeting candidate (TPST-4903) currently in a Phase 1 study for relapsed or refractory multiple myeloma. This exercise follows encouraging preliminary clinical data from 13 patients and expands Tempest's delivery capabilities alongside its existing LNP platform.
Counterparty
Hebei Senlang Biotechnology Co., Ltd.
“Our decision to exercise this option and obtain an exclusive license reflects our confidence in the platform and the differentiating clinical observations from the lead program.”
Matt Angel, Ph.D., President and Chief Executive Officer of Tempest
“With the addition of this clinical-stage lentiviral platform alongside our targeted LNP platform, we have expanded our capabilities to develop in vivo immune reset therapies for cancer and autoimmune disease.”
Matt Angel, Ph.D., President and Chief Executive Officer of Tempest
Vor Biopharma Licensing Deal with RemeGen Co., Ltd. Worth $10M
Vor Biopharma expanded its existing partnership with RemeGen by entering into an amended and restated license agreement to add RC298, a next-generation dual BAFF/APRIL inhibitor, to its exclusive development and commercialization rights outside of Greater China. Vor Bio will pay an upfront cash payment of $10 million and issue a pre-funded warrant for 2.3 million shares, with RemeGen eligible for up to $630 million in development and regulatory milestones plus tiered royalties.